NCT00596401

Completed

The Preventive Effect of Helicobacter Pylori Eradication on ...

Showa Inan General Hospital Source

Compare

Other study identifiers

Sponsor study identifier

sihp20076

Study Type

observational

Actual enrollment (reported)

3,000

Locations

1 country

Sites

1

Timeline

Study Start

September 2007

Actual (reported)

Primary Completion

December 31, 2021

Actual (reported)

Study Completion

December 31, 2021

Actual (reported)

Brief Summary

Recently, the preventive effect of Helicobacter pylori (Hp) eradication treatment on the incidence of gastric cancer has been reported. By Hp eradication treatment being performed for Hp-infected people in Iijima town, we will evaluate whether the incidence of gastric cancer and/or the medical care cost can be reduced as compared with those in the previous years.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 3,000 participants
Study completion date: December 31, 2021
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
September 2007
Actual (reported)
First Submitted
January 8, 2008
Actual (reported)
First Posted
January 17, 2008
Actual (reported)
Primary Completion
December 31, 2021
Actual (reported)
Study Completion
December 31, 2021
Actual (reported)

Last Updated: February 21, 2022
Status Verified: February 2022
Last Update Submitted: February 18, 2022

Conditions

Eradication Gastric Cancer Helicobacter Pylori Medical Care Cost

Outcome Measures

Primary Outcomes (1)

the annual incidence of gastric cancer in Iijima town
10 years

Secondary Outcomes (1)

The annual medical care cost in Iijima town
10 years

Study Arms (3)

1

HP eradication group

2

No eradication group

3

No Hp group

Eligibility Criteria

Age19 Years - 69 Years

Sexall

Healthy VolunteersYes

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

People who live in Iijima town

You may qualify if:

People who live in Iijima town at their age of 19 to 69 years

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Showa Inan General Hospital
Otherlead

Study Sites (1)

Showa Inan General hospital

Komagane, Nagano, 399-4191, Japan

Biospecimen

Retention: SAMPLES WITHOUT DNA

serum

MeSH Terms

Conditions

Stomach Neoplasms

Condition Hierarchy (Ancestors)

Gastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesStomach Diseases

Study Officials

Akira Horiuchi, M.D.
Showa Inan General Hospital
STUDY DIRECTOR

Enrollment

3,000 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Digestive Disease Center

Study Record Dates

First Submitted

January 8, 2008

First Posted

January 17, 2008

Study Start

September 2007

Actual (reported)

NCT00287768

Phase III Study of Docetaxel + S-1 vs. S-1 for Advanced Gastric Cancer

Phase 3Completed

NCT00687843

Study of TS-1 or TS-1 + PSK for Gastric Cancer Patients

Phase 3Unknown

NCT00845611

Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Gastric Cancer

Phase 1Completed

NCT00503321

Phase II Study of TS-1 Therapy and TS-1+PSK Therapy Against Advanced Gastric Carcinoma

Phase 2/3Terminated

NCT01065688

A Trial of Reconstruction After Distal Gastrectomy for Gastric Cancer

Phase 3Completed

NCT00681252

Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer

Phase 1/2Completed

Primary Completion

December 31, 2021

Actual (reported)

Study Completion

December 31, 2021

Actual (reported)

Last Updated

February 21, 2022

Record last verified: 2022-02

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT00596401
Data provider: ClinicalTrials.gov
Source updated: 2022-02-21
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:40:34 UTC

Locations

JP(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (3)

1

2

3

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Source record

Locations